SpyGlass Pharma, Inc.
For the period ended Jun 30, 2026. Filed Aug 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 6, 2026
SGP$34.18-10.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Conde nsed Statem ents of Operations and Comprehensive Loss
(in thousands, except share and per share data)
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Operating expenses | ||||
| Research and development | $10,942 | $7,333 | $19,484 | $13,385 |
| General and administrative | 11,025 | 1,964 | 17,892 | 3,335 |
| Total operating expenses | 21,967 | 9,297 | 37,376 | 16,720 |
| Loss from operations | (21,967) | (9,297) | (37,376) | (16,720) |
| Other income (expense) | ||||
| Interest income | 2,103 | 622 | 3,694 | 748 |
| Change in fair value of redeemable convertible preferred stock tranche liability | — | — | — | (1,526) |
| Total other income (expense) | 2,103 | 622 | 3,694 | (778) |
| Loss before income tax | (19,864) | (8,675) | (33,682) | (17,498) |
| Income tax provision | — | — | — | — |
| Net loss and comprehensive loss | $(19,864) | $(8,675) | $(33,682) | $(17,498) |
| Net loss per share | ||||
| Weighted average common stock outstanding, basic and diluted | 33,439,543 | 2,277,521 | 26,721,021 | 2,253,711 |
| Net loss per share, basic and diluted | $(0.59) | $(3.81) | $(1.26) | $(7.76) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.